Clinicopathologic Spectrum of Lung Malignancies and Detection of EGFR Mutations in Non-Small Cell Lung Cancers from a Tertiary Care Centre

Sunitha Gattigorla; Leelarani Veeramachaneni; V R N Krishna Kanth Gundimeda; Jyothi Nirmala; Vaibhav Shandilya; Shreyasi Gopikonda

doi:10.21276/apalm.3491

Authors

Sunitha Gattigorla Department of Pathology, ESIC Medical College, Sanathnagar, Hyderabad, Telangana, India
Leelarani Veeramachaneni Department of Pathology, ESIC Medical College, Sanathnagar, Hyderabad, Telangana, India
V R N Krishna Kanth Gundimeda Department of Pathology, ESIC Medical College, Sanathnagar, Hyderabad, Telangana, India
Jyothi Nirmala Department of Pathology, ESIC Medical College, Sanathnagar, Hyderabad, Telangana, India
Vaibhav Shandilya Department of Pathology, ESIC Medical College, Sanathnagar, Hyderabad, Telangana, India
Shreyasi Gopikonda Department of Pathology, ESIC Medical College, Sanathnagar, Hyderabad, Telangana, India

DOI:

https://doi.org/10.21276/apalm.3491

Keywords:

Lung cancers, EGFR mutation, Adenocarcinoma lung, Exons 19, 20 and 21, Squamous cell carcinoma lung

Abstract

Background: Lung cancer is the most common cause of cancer-related deaths. Lung cancers are increasingly being studied for molecular targets that are amenable to treatment. EGFR mutation is one such target, and we have attempted to determine the histological types and EGFR mutations in lung cancer patients. Aim of the study: To study the patient demographics, clinicopathological profile, histological subtypes, and the EGFR mutations in lung cancers.

Materials and Methods: The patient details were collected from all biopsy-proven cases of lung cancers. The histopathological types of lung cancers were noted. The EGFR mutation assay was done by polymerase chain reaction (PCR) and pyrosequencing, and findings were noted.

Results: Our study comprised 93 cases, with 64 male and 29 female patients, and the M:F ratio was 2.2:1. NSCLC were 97%, and small cell lung cancers were 3%. Among the NSCLC, adenocarcinomas were more common than squamous cell carcinomas. EGFR mutations were observed in 21.5% of cases. Most (95%) EGFR mutations were seen in adenocarcinomas, and 5% were seen in squamous cell carcinoma. Exon 19 was more commonly affected (60% of cases).

Conclusion: Lung cancers are twice as common in males as in females. Among NSCLC, adenocarcinomas are more common, and one-fifth of adenocarcinomas are positive for EGFR mutations, with exon 19 mutation being the most common. EGFR mutation testing is encouraged in all lung cancer patients in view of available treatment options.

References

1. International Agency for Research on Cancer. World Health Organization. Lung Factsheet: Globocan; 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/lung-cancer

2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

3. International Agency for Research on Cancer. World Health Organization. WHO South-East Asia Region: Globocan; 2018.

4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

5. Dattatreya SP, Bansal R, Vamsy M, Vaniawala S, Nirni SS, Dayal M, et al. Clinicopathological profile of lung cancer at a tertiary care center. Indian J Cancer. 2018;55(3):273–5.

6. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.

7. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–46.

8. Ramani V, Bijit C, Vinu S, Belagutti JS, Radhe-Shyam N. Clinicopathological profile of lung cancers at an institute from South India—a record-based retrospective cohort study. Adv Lung Cancer. 2020;9:41–54.

9. Dash NC, Dash M, Trilochan BP, Dhone PG, Mishra B, Patnaik J. Study on primary non-small cell lung cancer with special reference to immunohistochemistry, EGFR mutation and K-RAS mutation in a tertiary care hospital. Int J Health Sci. 2022;6(S6):6450–6.

10. Noronha V, Pinninti R, Patil VM, Joshi A, Prabhash K. Lung cancer in the Indian subcontinent. South Asian J Cancer. 2016;5:95–103.

11. Babu G, Lakshmaiah KC, Kamath M, Lokanath D. Metastatic lung cancer at a tertiary cancer centre in South India. J Thorac Oncol. 2017;12(Suppl):S484–5.

12. Kumar BS, Abhijit M, Debasis D, Abinash A, Ghoshal AG, Kumar DS, et al. Clinico-pathological profile of lung cancer in a tertiary medical centre in India: analysis of 266 cases. J Dent Oral Hyg. 2011;3:30–3.

13. Mohan A, Latifi AN, Guleria R. Increasing incidence of adenocarcinoma lung in India: following the global trend? Indian J Cancer. 2016;53:92–5.

14. Xie X, Li X, Tang W, Xie P, Tan X. Primary tumor location in lung cancer: the evaluation and administration. Chin Med J (Engl). 2021;135(2):127–36.

15. Ganguly S, Biswas B, Bhattacharjee S. Clinicopathological characteristics and treatment outcome in small cell lung cancer: a single institutional experience from India. Lung India. 2020;37:134–9.

16. Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, Chandrani P, et al. Frequency of EGFR mutations in 907 lung adenocarcinoma patients of Indian ethnicity. PLoS One. 2013;8:e76164.

17. Zhang YL, Yuan JQ, Wang KF, Fu XH, Han XR, Threapleton D, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985–93.

18. Doval D, Prabhash K, Patil S, Chaturvedi H, Goswami C, Vaid A, et al. Clinical and epidemiological study of EGFR mutations and EML4 ALK fusion genes among Indian patients with adenocarcinoma of the lung. Onco Targets Ther. 2015;8:117–23.

19. Aggarwal S, Patil S, Minhans S, Pungliya M, Soumitra N. A study of EGFR mutation in non-smoker NSCLC: striking disparity between North and South India patients. J Clin Oncol. 2012;30(Suppl):E18041.

20. Tsubata Y, Tanino R, Isobe T. Current therapeutic strategies and prospects for EGFR mutation-positive lung cancer based on the mechanisms underlying drug resistance. Cells. 2021;10(11):3192.

21. Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, Goto K. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res. 2015;4:156–64.

22. Bhatt AD, Pai R, Rebekah G, Nehru GA, Dhananjayan S, Samuel A, et al. Clinicopathologic features of non-small cell lung cancer in India and correlation with epidermal growth factor receptor mutational status. Indian J Cancer. 2013;50(2):94–101.

23. Li AR, Chitale D, Riely GJ, Pao W, Miller VA, Zakowski MF, et al. EGFR mutations in lung adenocarcinomas: clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression. J Mol Diagn. 2008;10(3):242–8.

24. Yoon HY, Ryu JS, Sim YS, Kim D, Lee SY, Choi J, et al. Clinical significance of EGFR mutation types in lung adenocarcinoma: a multi-centre Korean study. PLoS One. 2020;15(2):e0228925.

25. Goud KI. Molecular diagnosis of lung cancers. Mol Enzymol Drug Targets. 2015;1:1–8.

26. Kaler AK, Patel K, Patil H, Tiwarekar Y, Kulkarni B, Hastak M, et al. Mutational analysis of EGFR mutations in non-small cell lung carcinoma—an Indian prospective of 212 patients. Int J Environ Res Public Health. 2023;20:758.

27. Xia J, Li H, Ji Y. Clinicopathologic characteristics and EGFR mutations in lung cancer patients aged below 45 years. Curr Probl Cancer. 2019;43(4):363–70.

28. Mohan A, Garg A, Gupta A, Sahu S, Choudhari C, Vashistha V, et al. Clinical profile of lung cancer in North India: a 10-year analysis of 1862 patients from a tertiary care center. Lung India. 2020;37(3):190–7.